levodopa
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Ligand Summary
NCATS Inxight: Drugs: levodopa
PubChem: 6971033
ChEMBL: CHEMBL1009
DrugCentral: 1567
LyCHI: H7AMHQ2Y882F
Target Activities
Items per page:
10
1 – 3 of 3
TDP1
Tyrosyl-DNA phosphodiesterase 1
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Potency | 6.3 | None, None:None:None | ||||
DRD2
D(2) dopamine receptor
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
AGONIST | ||||||
DRD1
D(1A) dopamine receptor
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
AGONIST | ||||||